Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nicomethanol hydrofluoride, frequently marketed under the trade name Fluorinol, is an organic fluoride compound specifically developed for oral hygiene and therapeutic dentistry. Unlike inorganic fluorides such as sodium fluoride, nicomethanol hydrofluoride acts as a high-affinity vector that facilitates the rapid and intense fixation of fluoride ions onto dental enamel. Developed by Pierre Fabre, the molecule's structure allows for superior fluoride uptake compared to traditional sources, leading to the formation of a robust fluorapatite layer. This process significantly enhances the remineralization of incipient carious lesions and strengthens the tooth's resistance to acid attacks from plaque bacteria. It is widely utilized in professional and consumer dental products, including toothpastes and mouthwashes, to prevent dental caries and alleviate tooth hypersensitivity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nicomethanol hydrofluoride.